Brca-Mutated Tumor

Breast cancer survivors who harbor BRCA gene mutation are at elevated risk for second primary cancers, according to study results.

The FDA approved olaparib in combination with abiraterone acetate and prednisone or prednisolone for men with suspected deleterious or deleterious BRCA-mutated metastatic castration-resistant prostate cancer.